Neuropsychiatric events linked to Relenza - Xagena Medical News

GlaxoSmithKline has informed Healthcare Professionals of a recent update to the Relenza ( Xanamivir ) Inhalation Powder package insert. The revision to the product label is a result of information about adverse events reported during postmarketing clinical ...

Biota Announces Inavir® Royalty Results for Q312 and Phase III Prevention Study Update - Market Wire

Biota developed the first-in-class neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza. Biota research breakthroughs include a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease and ...

Theraclone Passes First Clinical Test with Flu-Fighting Antibody - Xconomy

While there are already a couple of antiviral pills on the market—Roche’s oseltamivir phosphate (Tamiflu) or GlaxoSmithKline’s zanamivir (Relenza)—scientists worry about mutant strains like H5N1 “bird flu” that could emerge and ...

The Global Antivirals Market Expected To Reach $30 Billion By 2017 - OfficialWire

Some major patent expiries are expected during the forecast period, such as for Sustiva, Combivir, Tenofovir, Telbivudine, Tamiflu and Relenza. The patent expiries of these blockbuster drugs will trigger generic competition in the antivirals market ...

Another deadly pandemic a matter of when, not if - The Age

Many, many would die before the vaccine could be rolled out. The drugs that would help are the antivirals, such as Relenza and Tamiflu. They can treat a wide variety of flu viruses because they target part of the bug that doesn't tend to change.

Liquidia Studies Show PRINT® Engineered Particles Hold Promise in the Delivery of Respiratory Therapeutics - PharmiWeb

This was specifically demonstrated by comparing the aerosol characteristics of PRINT drug particles to those of the marketed product, Relenza, which has the active ingredient zanamivir. The PRINT-zanamivir inhalation powder showed a reduction in mass ...